LEQVIO 284 mg/1.5 ml is a Product of the Generic Inclisiran

LEQVIO 284 mg/1.5 ml belongs to the generic category of Inclisiran. This medicine should be used according to a doctor's advice. We have provided detailed information about the uses, dosage, effectiveness, side effects, precautions, drug interactions, storage conditions, and other important details of LEQVIO 284 mg/1.5 ml. Our goal is to present essential medicine information in one place for patients, caregivers, and healthcare professionals. To better understand Inclisiran and ensure the safe use of this medicine, please read the information below carefully and consult a healthcare professional when necessary.

Description of LEQVIO 284 mg/1.5 ml

LEQVIO 284 mg/1.5 ml may be available as a prescription or over-the-counter medicine, depending on local regulations and medical recommendations. It is used for the treatment and management of specific conditions or symptoms. The way this medicine is used may vary depending on the patient's condition and the advice of a healthcare provider. Detailed information about the approved uses, therapeutic applications, and other relevant details of LEQVIO 284 mg/1.5 ml is provided below to help users gain a clear understanding of this medicine.

What Is LEQVIO 284 mg/1.5 ml Indications and Uses?

LEQVIO 284 mg/1.5 ml (Inclisiran) is a small interfering RNA (siRNA) directed to proprotein convertase subtilisin kexin type 9 (PCSK9) mRNA indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH). pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH).

Pharmacology (Source, Chemical and Physical Composition) Of LEQVIO 284 mg/1.5 ml

LEQVIO 284 mg/1.5 ml (Inclisiran) is a double-stranded small interfering ribonucleic acid (siRNA), conjugated on the sense strand with triantennary N-Acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes. In hepatocytes, inclisiran utilizes the RNA interference mechanism and directs catalytic breakdown of mRNA for PCSK9. This increases LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and lowers LDL-C levels in the circulation.

Dosage And Administration of LEQVIO 284 mg/1.5 ml

The recommended dosage of LEQVIO 284 mg/1.5 ml (Inclisiran) for adults and pediatric patients aged 12 years and older is 284 mg administered as a single subcutaneous injection initially, again at 3 months, and then every 6 months. If a planned dose is missed by less than 3 months, administer Inclisiran and maintain dosing according to the patient’s original schedule. If a planned dose is missed by more than 3 months, restart with a new dosing schedule - administer Inclisiran initially, again at 3 months, and then every 6 months. Assess LDL-C when clinically indicated. The LDL-lowering effect of Inclisiran may be measured as early as 30 days after initiation and anytime thereafter without regard to timing of the dose.

Side Effects of LEQVIO 284 mg/1.5 ml

Common adverse reactions in clinical trials (≥ 3%): injection site reaction, arthralgia, and bronchitis.

Precautions And Warnings for LEQVIO 284 mg/1.5 ml

Hypersensitivity Reactions: Have been reported in patients treated with LEQVIO 284 mg/1.5 ml (Inclisiran). Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to seek medical attention promptly.

Use During Pregnancy and Lactation

Advise pregnant patients and patients who can become pregnant of the potential risk to a fetus. Advise patients to inform their healthcare provider of a known or suspected pregnancy to discuss if LEQVIO 284 mg/1.5 ml (Inclisiran) should be discontinued. There is no information on the presence of inclisiran in human milk, the effects on the breastfed infant, or the effects on milk production. Inclisiran was present in the milk of lactating rats in all dose groups.

Therapeutic Class

Other Anti-anginal & Anti-ischaemic drugs

Storage Conditions of It

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children. Pack Images: LEQVIO 284 mg SC Injection Thanks for using MedEx! How would you rate your experience so far?